伯氨喹剂量对无并发症间日疟患者复发风险的影响:系统综述与个体患者数据Meta分析
该系统综述与个体患者数据Meta分析纳入23项研究6879例患者,发现与未用伯氨喹相比,低总剂量(约3.5 mg/kg)和高总剂量(约7 mg/kg)伯氨喹均降低间日疟复发率,高剂量效果更优,但高日剂量组胃肠道症状报告率略高。
要点
- 第180天复发风险:未用伯氨喹51.0%,低总剂量19.3%,高总剂量8.1%。
- 高总剂量较低总剂量在高低复发周期性地区均更有效。
- 高日剂量(约1 mg/kg/天)胃肠道症状报告率10.9%,高于未用组的4.0%。
核心结论
- 将伯氨喹总剂量从3.5 mg/kg增至7 mg/kg可在多数流行区使间日疟复发减少50%以上,伴有胃肠道症状的小幅增加。
研究设计与样本
- 系统综述与个体患者数据Meta分析,检索MEDLINE、Web of Science、Embase和Cochrane Central,纳入2000年1月1日至2023年6月8日发表的前瞻性临床研究。
- 纳入标准包括活性随访至少28天、多日每日给予伯氨喹、伯氨喹在杀裂殖体治疗7天内开始、单用或与氯喹或四种青蒿素联合疗法之一联用。
- 排除预防/ prophylaxis研究、重症疟疾患者及非计划试验的回顾性病历数据提取。
- 疗效分析纳入23项研究6879例患者(来自16个国家);耐受性分析纳入16项研究5609例患者(来自10个国家)。
主要发现
- 第180天首次间日疟复发风险:未用伯氨喹组51.0%(95%CI 48.2-53.9,n=1470),低总剂量组19.3%(16.9-21.9,n=2569),高总剂量组8.1%(7.0-9.4,n=2811),与伯氨喹疗程无关。
- 与未用伯氨喹相比,低剂量伯氨喹复发率更低(调整HR 0.21,95%CI 0.17-0.27;p<0.0001),高剂量伯氨喹复发率更低(HR 0.10,0.08-0.12;p<0.0001)。
- 在高和低复发周期性地区,高总剂量伯氨喹疗效均优于低总剂量。
- 第5-7天胃肠道症状报告率:未用组4.0%(95%CI 0.0-8.7,n=893),低日剂量组6.2%(0.5-12.0,n=737),中间日剂量组5.9%(1.8-10.1,n=1123),高日剂量组10.9%(5.7-16.1,n=1178)。
- 疗效分析23项研究中20项、耐受性分析16项研究中15项为低或不明确偏倚风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primaquine is used to eliminate Plasmodium vivax hypnozoites, but its optimal dosing regimen remains unclear. We undertook a systematic review and individual patient data meta-analysis to investigate the efficacy and tolerability of different primaquine dosing regimens to prevent P vivax recurrence. METHODS: For this systematic review and individual patient data meta-analysis, we searched MEDLINE, Web of Science, Embase, and Cochrane Central for prospective clinical studies of uncomplicated P vivax from endemic countries published between Jan 1, 2000, and June 8, 2023. We included studies if they had active follow-up of at least 28 days, and if they included a treatment group with daily primaquine given over multiple days, where primaquine was commenced within 7 days of schizontocidal treatment and was given alone or coadministered with chloroquine or one of four artemisinin-based combination therapies (ie, artemether-lumefantrine, artesunate-mefloquine, artesunate-amodiaquine, or dihydroartemisinin-piperaquine). We excluded studies if they were on prevention, prophylaxis, or patients with severe malaria, or if data were extracted retrospectively from medical records outside of a planned trial. For the meta-analysis, we contacted the investigators of eligible trials to request individual patient data and we then pooled data that were made available by Aug 23, 2021. We assessed the effects of total dose and duration of primaquine regimens on the rate of first P vivax recurrence between day 7 and day 180 by Cox's proportional hazards regression (efficacy analysis). The effect of primaquine daily dose on gastrointestinal symptoms on days 5-7 was assessed by modified Poisson regression (tolerability analysis). The study was registered with PROSPERO, CRD42019154470. FINDINGS: Of 226 identified studies, 23 studies with patient-level data from 6879 patients from 16 countries were included in the efficacy analysis. At day 180, the risk of recurrence was 51·0% (95% CI 48·2-53·9) in 1470 patients treated without primaquine, 19·3% (16·9-21·9) in 2569 patients treated with a low total dose of primaquine (approximately 3·5 mg/kg), and 8·1% (7·0-9·4) in 2811 patients treated with a high total dose of primaquine (approximately 7 mg/kg), regardless of primaquine treatment duration. Compared with treatment without primaquine, the rate of P vivax recurrence was lower after treatment with low-dose primaquine (adjusted hazard ratio 0·21, 95% CI 0·17-0·27; p<0·0001) and high-dose primaquine (0·10, 0·08-0·12; p<0·0001). High-dose primaquine had greater efficacy than low-dose primaquine in regions with high and low relapse periodicity (ie, the time from initial infection to vivax relapse). 16 studies with patient-level data from 5609 patients from ten countries were included in the tolerability analysis. Gastrointestinal symptoms on days 5-7 were reported by 4·0% (95% CI 0·0-8·7) of 893 patients treated without primaquine, 6·2% (0·5-12·0) of 737 patients treated with a low daily dose of primaquine (approximately 0·25 mg/kg per day), 5·9% (1·8-10·1) of 1123 patients treated with an intermediate daily dose (approximately 0·5 mg/kg per day) and 10·9% (5·7-16·1) of 1178 patients treated with a high daily dose (approximately 1 mg/kg per day). 20 of 23 studies included in the efficacy analysis and 15 of 16 in the tolerability analysis had a low or unclear risk of bias. INTERPRETATION: Increasing the total dose of primaquine from 3·5 mg/kg to 7 mg/kg can reduce P vivax recurrences by more than 50% in most endemic regions, with a small associated increase in gastrointestinal symptoms. FUNDING: Australian National Health and Medical Research Council, Bill & Melinda Gates Foundation, and Medicines for Malaria Venture.
引用
- Commons RJ, Rajasekhar M, Edler P, et al. Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis. Lancet Infect Dis. 2023. PMID: 37748496. doi:10.1016/S1473-3099(23)00430-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。